Bausch Health Companies Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount
Bausch Health Companies Inc. (BHC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount of $11.00 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges · last filed 2026-07-30
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, restructuring charges, amount for the quarter ending 2025-09-30 was $19.00M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, restructuring charges, amount for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, restructuring charges, amount for the quarter ending 2018-06-30 was $252.00M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, restructuring charges, amount for the quarter ending 2018-03-31 was $3.00M, a 99.53% decline year-over-year.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount 9 month |
|---|---|---|---|
| 2025-09-30 | $19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $11.00M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | -$8.00M 10-Q · filed 2026-07-30 | ||
| 2019-06-30 | $4.00M 10-Q · filed 2019-08-06 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $252.00M derived: sum of 2 quarters · filed 2019-11-04 | $255.00M 10-Q · filed 2019-11-04 |
| 2018-06-30 | $252.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $255.00M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $3.00M 10-Q · filed 2019-05-06 | ||
| 2017-09-30 | $1.40B 10-Q · filed 2017-11-07 | $1.40B derived: sum of 2 quarters · filed 2018-08-07 | $2.63B 10-Q · filed 2018-11-06 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $635.00M 10-Q · filed 2018-08-07 | |
| 2017-03-31 | $635.00M 10-Q · filed 2018-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |